(Press-News.org) Individuals who received a once-a-day oral weight loss drug lost up to 13% of their body weight over three months, the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) will hear.
Amycretin, which is being developed by the Danish pharmaceutical company Novo Nordisk A/S, mimics the action of two peptide hormones in one single molecule.
Amycretin is both an amylin and glucagon-like peptide-1 (GLP-1) receptor agonist. Both of these play a key role in appetite regulation and feeling of hunger and have been shown to lead to weight loss.
Currently, GLP-1 based treatment options are mainly administered via injections, a delivery method also used for the amylin-based treatments undergoing clinical development. To date, there are no tablet-form treatment options targeting both of these biologies.
In a single-centre, placebo-controlled, double-blinded phase 1 study, adult participants with a BMI of 25.0-39.9 kg/m2 without diabetes were randomised to receive amycretin or a placebo once-a-day for up to 12 weeks.
The study, which was conducted by Novo Nordisk A/S, and a clinical research unit in the US, consisted of single- and multiple ascending dose parts, where different doses of amycretin were tested orally: single-ascending dose (increasing from 1 mg a day to 25 mg)10-day multiple-ascending doses (investigating from 3 to 12 mg), and 12-week multiple-ascending doses (by introducing step wise dose escalation, investigating from a start dose of 3 mg and up to a final dose of 2x50 mg).
In the first-in-human trial, amycretin appeared to have a safe and tolerable profile in line with the drug receptor classes. Side-effects were mainly mild to moderate in severity and of gastrointestinal nature including nausea and vomiting.
At the end of the trial, average weight loss was greater with amycretin than with the placebo. Participants taking amycretin 50 mg reduced their body weight by 10.4%, on average, within 12 weeks of treatment, while those taking amycretin 2x50mg, the maximum dose tested, achieved a body weight reduction of 13.1%. This compares to an average weight loss of 1.1% among those taking placebo during the same time.
Notably, at the end of the treatment period, weight loss had not reached a plateau for participants taking amycretin, indicating the potential for further weight loss with extended use.
The study’s authors conclude that daily oral amycretin treatment in adults with overweight or obesity and without diabetes demonstrated a safe and tolerable profile in line with the drug receptor classes, and with notable reductions in body weight.
They add: “A single molecule that targets both amylin and GLP-1 biology in a tablet form could offer a more convenient approach to achieving better outcomes for individuals with overweight or obesity.
“However, larger and longer studies are needed to fully assess the drug’s safety profile and potential.”
Contact: Global Media & Stakeholder Communication, Novo Nordisk.
globalmedia@novonordisk.com
Contact: Tony Kirby in the EASD Press Office T) +44 7834 385827 E) tony.kirby@tonykirby.com
Notes to editors:
All co-authors are employees and shareholders of Novo Nordisk A/S
For full abstract, click here
END
Weight loss of up to 13% achieved in three months with once-a-day tablet, phase 1 trial finds
2024-09-10
ELSE PRESS RELEASES FROM THIS DATE:
Time-restricted eating improves blood sugar control in adults at risk of type 2 diabetes regardless of time of day
2024-09-10
Restricting the eating window to 8 hours a day significantly improves blood glucose control in adults at risk of type 2 diabetes irrespective of whether it is earlier or later in the day, according to a randomised crossover trial to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).
“Our study found that restricting eating to a window of 8 hours per day significantly improved the daily time spent in the normal blood glucose range and reduced fluctuations in blood glucose levels. However, altering the 8-hour restricted eating period ...
Individuals with complications of diabetes are at higher risk of gum disease, Danish study finds
2024-09-10
Gum disease is more common in individuals with microvascular complications of diabetes, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) and published in
The Journal of Dental Research has found.
Periodontitis is a chronic inflammatory disease that affects the gums and the bones supporting the teeth. It is caused by the accumulation of bacterial plaque, and if left untreated, it can lead to the destruction of the tissues that hold the teeth in place, ultimately resulting in tooth loss.
“This tooth loss can affect essential functions like chewing and speaking, while ...
Weight loss drug liraglutide is safe and effective in children under 12, study finds
2024-09-10
The obesity medication liraglutide is safe and effective in children aged 6 to <12 years, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), and published simultaneously in the New England Journal of Medicine (NEJM), has found.
Childen aged six to <12 years who took liraglutide for just over a year experienced a reduction in BMI of 7.4% compared to placebo and experienced improvements in blood pressure and blood sugar control.
The results of ...
Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal
2024-09-10
Results from a clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) show a striking improvement for patients who received chemotherapy before surgery to remove advanced squamous cell-type cancer of the nose or sinus. The European Society of Medical Oncology is highlighting the trial at its ESMO Congress 2024 in Barcelona, Spain. Surgery is required for these patients but at a high physical cost. Patients enrolled in this trial had signs that surgery would result in loss of the eye, the base of the skull bone, or both. However, in the randomized prospective trial EA3163, patients receiving chemotherapy ...
The glug of it all
2024-09-10
As Rohit Velankar, now a senior at Fox Chapel Area High School, poured juice into a glass, he could feel that the rhythmic glug, glug, glug was flexing the walls of the carton.
Rohit pondered the sound, and wondered if a container’s elasticity influenced the way its fluid drained. He initially sought the answer to his question for his science fair project, but it spiraled into something more when he teamed up with his father, Sachin Velankar, a professor of chemical and petroleum engineering at the University of Pittsburgh Swanson School of Engineering.
They set up an experiment ...
UTA to build netted drone facility in Fort Worth
2024-09-10
The University of Texas at Arlington is expanding its research and innovation capabilities by building a $2.3 million, state-of-the-art outdoor netted drone facility. The Maverick Autonomous Vehicle Research Center (MAVRC) will be located at the UT Arlington Research Institute (UTARI) in Fort Worth, with a planned completion date of January 2025.
“MAVRC will significantly and positively impact UTA’s presence in the region by supporting the university-industry-government-community ecosystem focused ...
Streamlining energy regulations on Native American reservations could help alleviate poverty
2024-09-10
MADISON–Land was once set aside as Native American reservations because it was undesirable and low in resources, but now interested Native Americans may have economic leverage in the growing industry of clean energy. A team of researchers led by UW–Madison professors Dominic Parker and Sarah Johnston quantified the economic potential of wind and solar energy projects on these lands and discussed the regulatory barriers for tribes wishing to tap into it.
“This is the first comprehensive ...
UT microbiologist Wilhelm honored as Fellow of the Royal Society of Canada
2024-09-10
Steven Wilhelm joins a distinguished roster this year with his election as a fellow of the Royal Society of Canada (RSC) Academy of Science. This recognition is the RSC’s highest honor in areas of arts, social sciences, humanities, and science.
“The RSC inducts fellows to help them build a better future in Canada and the world. As a native Canadian, this honor is the pinnacle of what I could have hoped for in my career,” said Wilhelm, the Kenneth and Blaire Mossman Professor in UT’s Department of Microbiology. “It also provides an opportunity for me to work with my collaborators ...
NCCN Policy Summit explores how to build an inclusive cancer center workplace culture that better serves everybody
2024-09-10
WASHINGTON, D.C. [September 10, 2024] — The National Comprehensive Cancer Network® (NCCN®) held an oncology policy summit today in Washington, D.C., focused on Advancing Diversity, Equity, and Inclusion in the Cancer Workforce. The event featured a keynote address from Tiffany Wallace, PhD, Branch Director, Disparities Research Branch, National Cancer Institute (NCI) Center for Cancer Health Equity. Panel discussions focused on how to establish and prioritize a culture of diversity, equity, inclusion, and belonging and maintain the commitment through a changing policy landscape. A series of ...
Games, puzzles and reading can slow cognitive decline in the elderly — even in those with mild cognitive impairment
2024-09-10
By Ann Kellett, Texas A&M University School of Public Health
The aging process can lead to diminished cognitive functioning for older adults. In addition, about 10 percent of people previously diagnosed with mild cognitive impairment develop Alzheimer’s disease or other forms of dementia every year.
Although a few studies have found that activities such as putting together jigsaw puzzles can protect against cognitive aging, the benefits of these activities in preventing or postponing cognitive ...